10699477

Source:http://linkedlifedata.com/resource/pubmed/id/10699477

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C1621958
pubmed:issue	2
pubmed:dateCreated	2000-5-8
pubmed:abstractText	To compare conventional fractionation with hypofractionation in patients with a glioblastoma multiforme. Endpoints of the analysis are overall survival and palliative effect.
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/8407192
pubmed:citationSubset	IM
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0167-8140
pubmed:author	pubmed-author:Andries BoschDD, pubmed-author:González GonzálezDD, pubmed-author:HulshofM CMC, pubmed-author:SchimmelE CEC
pubmed:issnType	Print
pubmed:volume	54
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	143-8
pubmed:dateRevised	2006-11-15
pubmed:meshHeading	pubmed-meshheading:10699477-Adult, pubmed-meshheading:10699477-Aged, pubmed-meshheading:10699477-Biopsy, pubmed-meshheading:10699477-Central Nervous System Neoplasms, pubmed-meshheading:10699477-Dose Fractionation, pubmed-meshheading:10699477-Glioblastoma, pubmed-meshheading:10699477-Humans, pubmed-meshheading:10699477-Middle Aged, pubmed-meshheading:10699477-Neoplasm Recurrence, Local, pubmed-meshheading:10699477-Neoplasm Staging, pubmed-meshheading:10699477-Patient Satisfaction, pubmed-meshheading:10699477-Prognosis, pubmed-meshheading:10699477-Prospective Studies, pubmed-meshheading:10699477-Relative Biological Effectiveness, pubmed-meshheading:10699477-Survival Rate, pubmed-meshheading:10699477-Tomography, X-Ray Computed
pubmed:year	2000
pubmed:articleTitle	Hypofractionation in glioblastoma multiforme.
pubmed:affiliation	Department of Radiotherapy, Academic Medical Centre, University of Amsterdam, P.0. Box 22700, 1100 DE, Amsterdam, The Netherlands.
pubmed:publicationType	Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Clinical Trial, Phase II